{
    "clinical_study": {
        "@rank": "23381", 
        "acronym": "REDUCE LAP-HF", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Treatment with the IASD device"
        }, 
        "brief_summary": {
            "textblock": "The objective of this clinical study is to evaluate the safety and performance of the IASD\n      System II in the treatment of heart failure patients with elevated left atrial pressure, who\n      remain symptomatic despite appropriate medical management."
        }, 
        "brief_title": "REDUCE LAP-HF TRIAL: A Study to Evaluate the DC Devices, Inc. IASD\u2122 System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Chronic symptomatic Heart Failure (HF) documented by one or more of the following:\n\n               1. New York Heart Association (NYHA) Class II/III/ambulatory class IV symptoms\n                  (Paroxysmal nocturnal dyspnea, Orthopnea, Dyspnea on mild or moderate exertion)\n                  at screening visit; or signs (Any rales post cough, Chest x-ray demonstrating\n                  pulmonary congestion,) within past 12 months;\n\n               2. One hospital admission for which HF was a major component of the hospitalization\n                  within the 12 months prior to study entry (transient heart failure in the\n                  context of myocardial infarction does not qualify);\n\n               3. Chronic or intermittent treatment with a loop diuretic\n\n          2. Age \u2265 40 years old\n\n          3. Left ventricular ejection fraction (obtained by echocardiography) \u2265 40%\n\n          4. Elevated left ventricular filling pressures with a gradient compared to CVP\n             documented by :\n\n               1. PCWP or LVEDP at rest  \u2265 15 mmHg, and greater than CVP, OR\n\n               2. PCWP during supine bike exercise \u2265 25mm Hg, and CVP < 20 mm Hg\n\n        Key Exclusion Criteria:\n\n        3. Severe heart failure defined as:\n\n          1. ACC/AHA/ESC Stage D heart failure, Non-ambulatory NYHA Class IV HF;\n\n          2. Fick Cardiac Index  < 2.2 L/min/m2\n\n          3. Requiring inotropic infusion (continuous or intermittent) within the past 6 months\n\n          4. Patient is on the cardiac transplant waiting list 4. Inability to perform 6 Minute\n             Walk Test 5. Known significant coronary artery disease (stenosis >70%) 6. History of\n             stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), or pulmonary\n             emboli within the past 6 months 7. Known severe carotid artery stenosis (> 70%) 8.\n             Presence of significant valve disease defined by echocardiography as: a) Mitral valve\n             regurgitation defined as grade >2+ MR b) Tricuspid valve regurgitation defined as\n             grade  \u2265 2+ TR; c) Aortic valve disease defined as \u2265 2+ AR or moderate AS"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913613", 
            "org_study_id": "2013-01"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "intervention_name": "IASD", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Homolka Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France"
                    }, 
                    "name": "CHU de Nantes"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "France"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "REDUCE LAP-HF TRIAL: A Study to Evaluate the DC Devices, Inc. IASD\u2122 System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure", 
        "overall_contact": {
            "email": "jkomtebedde@dcdevicesinc.com", 
            "last_name": "Jan Komtebedde, DVM"
        }, 
        "overall_contact_backup": {
            "email": "akulis@dcdevicesinc.com", 
            "last_name": "Anne Kulis"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Austria: Ethikkommission", 
                "Denmark: Danish Health and Medicines Authority", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes", 
                "Denmark: Ethics Committee", 
                "France: The Commission nationale de l\u2019informatique et des libert\u00e9s", 
                "Germany: Ethics Commission", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: Federal Office for Radiation Protection", 
                "Greece: Ethics Committee", 
                "Greece: National Organization of Medicines", 
                "Netherlands: Dutch Health Care Inspectorate", 
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "New Zealand: Medsafe", 
                "New Zealand: Ethics Committee", 
                "Poland: Ethics Committee", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "subjects who experience major adverse cardiac and cerebrovascular events (MACCE) defined as death, stroke, MI; or subjects who experience a systemic embolic event (excluding pulmonary thromboembolism)", 
            "measure": "MACCE", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "DC Devices, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "DC Devices, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}